Comparable stake leader
John Simard
SEC ownership of XBiotech Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001626878.
Disclosed value leader
John Simard
Comparable rows
10/20
Latest evidence
30 Jun 2026
- Public ticker
- XBIT on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
John Simard
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
10 of 20
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
John Simard
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001626878
- Issuer location
- Austin, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of XBiotech Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
John Simard
Disclosed value leader
John Simard
Comparable rows
10/20
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 18%
10 rows are not safely comparable across share classes.
13D/G row: John Simard
Showing 1-8 of 20 holder rows.
Quick read
John Simard leads the comparable SEC ownership view at 18%.
10 of 20 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens John Simard's linked filing trail.
Comparable ownership
Top 5
John Simard
18%
W. Thorpe McKenzie
9.8%
BlackRock, Inc.
0.99%
STATE STREET CORP
0.23%
Bank of New York Mellon Corp
0.12%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 20 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| John Simard |
13D/G
3/4/5
Chief Executive Officer, Director, 10%+ Owner
|
18%
|
$13,784,658
5,719,775 shares
|
-$2,180,460 | 31 Dec 2025 |
| W. Thorpe McKenzie |
13D/G
3/4/5
Director, 10%+ Owner
|
9.8%
|
$7,245,084
3,006,259 shares
|
+$45,188 | 31 Dec 2025 |
| BlackRock, Inc. |
13F
Company
|
0.99%
|
$738,636
321,146 shares
|
— | 30 Jun 2026 |
| STATE STREET CORP |
13F
Company
|
0.23%
|
$167,914
73,006 shares
|
— | 30 Jun 2026 |
| Bank of New York Mellon Corp |
13F
Company
|
0.12%
|
$90,517
39,355 shares
|
— | 30 Jun 2026 |
| GSA CAPITAL PARTNERS LLP |
13F
Company
|
0.09%
|
$71,000
30,654 shares
|
— | 30 Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ |
13F
Company
|
0.08%
|
$57,500
25,000 shares
|
— | 30 Jun 2026 |
| Thomasville National Bank |
13F
Company
|
0.04%
|
$30,705
13,350 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 16 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to XBiotech Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Thomas Martin Kuendig
Net 12M change
$0
Latest report
01 Oct 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Thomas Martin Kuendig | Director | $1,017,000 | Mixed | 01 Oct 2025 | ||
| Craig Evan Rademaker | Director | $579,638 | Mixed | 01 Oct 2025 | ||
| Angela Hu | Principle Financial Officer | $298,605 | Mixed | 10 Feb 2023 | ||
| Jan-Paul Waldin | Director | Mixed | 20 Jun 2024 | |||
| W. Thorpe McKenzie | Director, 10%+ Owner | Mixed | 20 Jun 2024 | |||
| Donald H. MacAdam | Director | Mixed | 20 Jun 2024 | |||
| Tevi David Troy | Director | Mixed | 01 Oct 2025 | |||
| David Spencer Soffer | Director | Mixed | 01 Oct 2025 | |||
| Peter Libby | Director | Mixed | 20 Jun 2024 | |||
| John Simard | Chief Executive Officer, Director, 10%+ Owner | Mixed | 03 Jan 2024 | |||
| Queena Han | VP Finance & HR | Mixed | 19 Nov 2021 | |||
| Sushma Shivaswamy | Chief Scientific Officer | Mixed | 10 Feb 2023 |
Recent insider transactions for XBiotech Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Craig Evan Rademaker | XBIT | Director Stock Option | Award | 92,104 | 92,104 | 01 Oct 2025 | Direct | |||
| David Spencer Soffer | XBIT | Director Stock Option | Award | 51,000 | 51,000 | 01 Oct 2025 | Direct | |||
| Thomas Martin Kuendig | XBIT | Director Stock Option | Award | 79,115 | 79,115 | 01 Oct 2025 | Direct | |||
| Tevi David Troy | XBIT | Director Stock Option | Award | 56,000 | 56,000 | 01 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.